Gina M. Mantia-Smaldone

Oncology

2701 Dekalb Pike
East Norriton, PA 19401

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 13, 2026

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 05, 2025

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 19, 2024

Juntas Contra el Virus del Papiloma Humano: protocol for a pilot randomized controlled trial of an HPV self-sampling intervention for underscreened Latinas.

Juntas Contra el Virus del Papiloma Humano: protocol for a pilot randomized controlled trial of an HPV self-sampling intervention for underscreened Latinas.

Journal: Pilot and feasibility studies

Published: March 06, 2024

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: December 11, 2023

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

Journal: Gynecologic oncology

Published: November 29, 2023

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Journal: Gynecologic oncology

Published: October 03, 2022

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.

Journal: Gynecologic oncology

Published: July 01, 2022

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.

Journal: Gynecologic oncology

Published: May 17, 2022

Perceived importance of weight loss and exercise among endometrial cancer survivors with overweight or obesity: Implications for lifestyle modification interventions.

Perceived importance of weight loss and exercise among endometrial cancer survivors with overweight or obesity: Implications for lifestyle modification interventions.

Journal: Obesity science & practice

Published: May 02, 2022

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.

Journal: Diagnostics (Basel, Switzerland)

Published: January 25, 2022

Showing 1-12 of 38

Last Updated: 09/26/2026